Tecnotree Continues to Deliver Stable Q1 2025 Performance With Improved Free Cash Flow and Strategic Market Expansion
29.4.2025 10:59:00 CEST | Business Wire | Press Release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced its financial results for the first quarter of 2025, demonstrating resilient financial performance with significant improvement in free cash flow and strategic progress in market diversification.
Q1 Results
- Net sales of EUR 16.9 million (16.3) +3.7% Year on Year, in constant currency, EUR 17.1 million, +4.6% Year on Year.
- Operating profit of EUR 4.5 million (4.4) +2.3% Year on Year.
- Operating margin of 26.9% (27.2%).
- Foreign exchange losses reduced to EUR 1.4 million (1.7).
- Net income EUR 1.5 million (1.6) -5.6% Year on Year.
- Gross cash flow from operations EUR 6.4 million (1.0).
- Positive free cash flow of EUR 1.0 million (-4.7).
- Earnings per share EUR 0.1 (0.1).
- Order book at the end of the period EUR 70.3 million (74.8).
Tecnotree recorded a consistent cashflow performance, supported by enhanced collections and disciplined cost management. DSO (Days Sales Outstanding) reduced significantly to 155 days from 216 days in the comparative quarter, contributing to the free cash flow turnaround. Capex to Sales ratio was reduced to 14.7%, from 20.8% in Q1 2024, reflecting the maturity and stability of Tecnotree's digital product stack.
Strategically, Tecnotree made significant progress in diversifying its order backlog geographically. The company increased its Europe & Americas backlog to EUR 12.1 million from EUR 8.7 million in Q1 2024, while purposefully managing exposure to frontier market risks. As a result, the portion of revenues booked in volatile currencies fell sharply to 15%, down from 45% in the previous year.
In line with its transformation towards a stable, recurring revenue model, Tecnotree maintained its Annual Recurring Revenue (ARR) at EUR 7.6 million. The company continues to focus on expanding license-based revenues and driving adoption of its digital platforms under the ODA (Open Digital Architecture) framework.
Tecnotree’s innovation leadership was further recognized by industry bodies such as TMForum and Gartner for its advancements in AI, 5G network monetization, and enterprise digital platforms. Tecnotree is nominated as a Finalist in the TM Forum Excellence Awards for Excellence in ODA implementation with MTN Group for its implementation across multiple Opcos. Tecnotree also won the Telecom Vendor of the Year for its implementation of the Tecnotree Moments platform for GenAi led campaign management at the Asia Telecom Awards. Further Tecnotree was recognised in the Gartner Market Guide for Revenue Management and Monetisation 2025. Tecnotree was also for the first time recognised in the Gartner Market Guide for CSP Marketplaces, validating our vision and investment strategy once again.
Padma Ravichander, CEO of Tecnotree said, "I am particularly pleased to highlight our consistent performance and focus to generate four consecutive quarters of positive free cash flow of EUR 1.0 million, a substantial improvement from the negative EUR 4.7 million in the same period last year. Our Net sales demonstrates a resilient start to 2025 with a 3.7% year-on-year increase, driven by a strategic focus on high-margin license revenue and geographic diversification. Our Operating profit remained stable at EUR 4.5 million, reflecting successful margin management amid ongoing cost optimization initiatives. The Order backlog in Europe and the Americas grew strongly, reflecting success in market diversification, while our focus on reducing frontier market exposure and optimizing working capital contributed to a healthier balance sheet. DSO days fell by 28%, trade receivables declined by EUR 7.4 million year-on-year, and Capex/Sales reduced significantly, demonstrating the maturity of our digital product stack.
Our brand recognition continues to strengthen, with TMForum and Gartner accolades in areas such as AI, 5G monetization, and enterprise digital services. Tecnotree remains among the few ODA Heroes, leading the adoption of modern open digital frameworks. With confidence in achieving our 2025 full-year guidance targets, including margin expansion, growth in recurring revenues, and further free cash flow improvement, Tecnotree is well-positioned for sustainable long-term value creation. Our bid pipeline remains strong and we expect to see the order book bounce back in the near term.”
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree leads the way on the TM Forum Open API Conformance with 59 certified Open APIs including 9 real-world open APIs, a testament to the company's commitment to excellence, and continuously striving to deliver differentiated experiences and services to both CSPs and DSPs. Our agile and open-source digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on the Helsinki Nasdaq (TEM1V).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250429609970/en/
Contacts
Prianca Ravichander, Tecnotree CMO
Email: marketing@tecnotree.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom